title: Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicin.
abstract: Doxorubicin remains an important part of chemotherapy regimens in the clinic and is considered an effective agent in the treatment of acute lymphoblastic leukemia (ALL). Although the cellular responses induced by doxorubicin treatment have been investigated for years, the precise mechanisms underlying its cytotoxicity and therapeutic activity remain unclear. Here we utilized mass spectrometry, together with stable isotope labeling by amino acids in cell culture (SILAC), to analyze comparatively the protein expression in Jurkat-T cells before and after treatment with a clinically relevant concentration of doxorubicin. We were able to quantify 1066 proteins in Jurkat-T cells with both forward and reverse SILAC measurements, among which 62 were with significantly altered levels of expression induced by doxorubicin treatment. These included the up-regulation of core histones, heterogeneous nuclear ribonucleoproteins, and superoxide dismutase 2 as well as the down-regulation of hydroxymethylglutaryl-CoA synthase and farnesyl diphosphate synthase. The latter two are essential enzymes for cholesterol biosynthesis. We further demonstrated that the doxorubicin-induced growth inhibition of Jurkat-T cells could be rescued by treatment with cholesterol, supporting that doxorubicin exerts its cytotoxic effect, in part, by suppressing the expression of hydroxymethylglutaryl-CoA synthase and farnesyl diphosphate synthase, thereby inhibiting the endogenous production of cholesterol. The results from the present study provide important new knowledge for gaining insights into the molecular mechanisms of action of doxorubicin.
authors.affiliation: Department of Chemistry, University of California, Riverside, CA 92521-0403, USA.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Dong
authors.forename: Lei
authors.initials: L
authors.lastname: Xiong
authors.forename: Xinning
authors.initials: X
authors.lastname: Jiang
authors.forename: Yinsheng
authors.initials: Y
authors.lastname: Wang
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D002784:Cholesterol / Q000096:biosynthesis / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D019169:Jurkat Cells; D053858:Metabolic Networks and Pathways / Q000187:drug effects* / Q000235:genetics; D040901:Proteomics / Q000379:methods*; D013601:T-Lymphocytes / Q000737:chemistry*
chemical_list: D004317:Doxorubicin; D002784:Cholesterol
references.citation: J Proteome Res. 2010 Feb 5;9(2):1129-37
references.pmid: 20050688
references.citation: Annu Rev Biochem. 2003;72:743-81
references.pmid: 12676796
references.citation: Methods. 2003 Feb;29(2):124-30
references.pmid: 12606218
references.citation: Cancer Lett. 2002 Jul 8;181(1):95-107
references.pmid: 12430184
references.citation: Proc Can Cancer Conf. 1967;7:152-62
references.pmid: 6047861
references.citation: Mol Pharmacol. 1994 Apr;45(4):649-56
references.pmid: 8183243
references.citation: Proc Natl Acad Sci U S A. 1982 Jun;79(12):3823-7
references.pmid: 6954525
references.citation: Mol Cell Proteomics. 2002 May;1(5):376-86
references.pmid: 12118079
references.citation: Circ Res. 1998 Sep 7;83(5):516-22
references.pmid: 9734474
references.citation: Crit Rev Oncol Hematol. 1991;11(1):43-64
references.pmid: 1831987
references.citation: J Proteome Res. 2008 Sep;7(9):3729-36
references.pmid: 18642942
references.citation: J Lipid Res. 1988 Aug;29(8):1005-11
references.pmid: 3183514
references.citation: Prog Exp Tumor Res. 1978;22:275-316
references.pmid: 209495
references.citation: Immunopharmacol Immunotoxicol. 2010 Sep;32(3):376-86
references.pmid: 20105085
references.citation: Proteomics. 2010 Jan;10(1):99-114
references.pmid: 20017144
references.citation: Cell Growth Differ. 1994 Jul;5(7):723-33
references.pmid: 7947387
references.citation: Biochemistry. 2009 Feb 17;48(6):1256-63
references.pmid: 19159229
references.citation: Cell Death Differ. 2006 Nov;13(11):1960-7
references.pmid: 16557274
references.citation: Cancer. 1985 Jun 15;55(12):2761-5
references.pmid: 3922612
references.citation: Mol Immunol. 2007 Jul;44(15):3682-90
references.pmid: 17524482
references.citation: Electrophoresis. 1995 Jun;16(6):1034-59
references.pmid: 7498127
references.citation: Biochim Biophys Acta. 1980 Jun 5;630(1):119-30
references.pmid: 6248123
references.citation: J Biol Chem. 1990 Nov 25;265(33):20277-84
references.pmid: 2243092
references.citation: Electrophoresis. 2003 Jul;24(14):2386-404
references.pmid: 12874874
references.citation: Cancer Chemother Rep. 1969 Feb;53(1):33-7
references.pmid: 5772652
references.citation: J Biol Chem. 2000 Oct 27;275(43):33585-92
references.pmid: 10899161
references.citation: Proc Natl Acad Sci U S A. 1977 Mar;74(3):956-60
references.pmid: 265587
references.citation: Eur J Immunol. 2009 Nov;39(11):3097-109
references.pmid: 19784949
references.citation: Proteomics. 2005 Feb;5(3):796-804
references.pmid: 15682461
references.citation: Exp Cell Res. 1984 Jul;153(1):91-8
references.pmid: 6610562
references.citation: J Proteome Res. 2003 Mar-Apr;2(2):173-81
references.pmid: 12716131
references.citation: Mol Cell Proteomics. 2005 Sep;4(9):1297-310
references.pmid: 15961381
references.citation: J Proteome Res. 2009 Mar;8(3):1565-76
references.pmid: 19199705
references.citation: Nat Methods. 2008 Apr;5(4):319-22
references.pmid: 18345006
references.citation: Pharmacol Rev. 2004 Jun;56(2):185-229
references.pmid: 15169927
references.citation: Eur J Clin Pharmacol. 1985;28(2):205-12
references.pmid: 3987800
references.citation: Mol Cell Proteomics. 2004 Dec;3(12):1154-69
references.pmid: 15385600
references.citation: Med Pediatr Oncol. 2002 May;38(5):329-37
references.pmid: 11979457
references.citation: Cancer Res. 1976 Aug;36(8):2891-5
references.pmid: 1277199
references.citation: Biochim Biophys Acta. 2009 Sep;1790(9):863-8
references.pmid: 19168116
references.citation: J Proteome Res. 2007 Jun;6(6):2105-12
references.pmid: 17472359
references.citation: Science. 1984 Oct 26;226(4673):466-8
references.pmid: 6093249
references.citation: J Proteome Res. 2002 Jan-Feb;1(1):21-6
references.pmid: 12643522
references.citation: Cancer Res. 1986 Feb;46(2):617-22
references.pmid: 2866834
references.citation: Nat Biotechnol. 1999 Oct;17(10):994-9
references.pmid: 10504701
references.citation: EMBO Rep. 2002 Mar;3(3):214-8
references.pmid: 11882539
references.citation: J Proteome Res. 2010 Jan;9(1):430-43
references.pmid: 19899826
references.citation: Mol Cancer. 2010 Mar 25;9:68
references.pmid: 20338046
references.citation: Circ Res. 1999 Feb 19;84(3):257-65
references.pmid: 10024299
references.citation: Proteomics. 2004 Oct;4(10):3246-67
references.pmid: 15378690